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Key messages
What is already known about this subject?
 ► B-type natriuretic peptide (BNP) or N-terminal pro-
BNP (NT-pro-BNP) levels during chronic phases of 
heart failure (HF), such as those levels at discharge 
from hospital, are now well established as prognos-
tic biomarkers of HF. But BNP on admission is less 
predictive in patients with acute decompensated HF 
(ADHF). Thus, on admission: in a vulnerable state of 
ADHF, there is still an unmet need for a biomarker 
for prediction of future clinical outcomes. Little has 
been known about the prognostic power of each 
natriuretic peptide molecular form including atrial 
natriuretic peptide (ANP) in patients with ADHF. We, 
therefore, compared predictability of circulating all 
measurable molecular forms of ANP and BNP for 
clinical outcome in patients with ADHF.
What does this study add?
 ► In this study, we were able to measure circulating 
levels of six molecular forms of ANP and BNP, includ-
ing pro-ANP, β-ANP, total ANP, total BNP, NT-pro-BNP 
and pro-BNP during the acute phase of HF. Our find-
ings showed that only pro-ANP on admission among 
the six measured natriuretic peptide forms was sig-
nificantly associated with composite adverse events 
independently of renal function. We also found that 
pro-ANP levels were strongly associated with left 
ventricular size and ejection fraction.
AbstrAct
Aims There are significant differences in how atrial 
(A-type) and B-type natriuretic peptide (ANP and BNP) are 
secreted and metabolised, but there is little information 
available about the relative clinical significance of the two 
peptides. The aim of the present study was to investigate: 
(1) the association between the circulating level of each 
ANP molecular form and patient clinical background 
and (2) their prognostic power for patients with acute 
decompensated heart failure (ADHF).
Methods We used specific chemiluminescence enzyme 
immunoassays to prospectively evaluate the levels of six 
bioactive molecular forms of ANP (pro-ANP, β-ANP and 
total ANP) and BNP (pro-BNP, N-terminal pro-BNP (NT-pro-
BNP) and total BNP) in plasma samples collected from 173 
patients with ADHF on their hospital admission.
Results We found that pro-ANP levels were strongly 
associated with left ventricular (LV) size and ejection 
fraction (p<0.001), but were not associated with left atrial 
size. Percent pro-ANP ([pro-ANP/total ANP]x100) was also 
associated with LV size and function. During the follow-up 
term (median: 469 days), composite adverse events (all 
causes of death or rehospitalisation for HF) occurred in 67 
patients (38.7 %). Pro-ANP was significantly associated 
with composite adverse events even after adjusting by 
estimated glomerular filtration rate (eGFR) (p<0.05). In 
contrast, NT-pro-BNP was not independent of eGFR in the 
multivariate analysis.
Conclusion Circulating levels of pro-ANP are strongly 
associated with LV function and clinical outcomes of 
patients with ADHF. These findings suggest that during 
the acute phases of HF, pro-ANP has a prognostic power 
comparable with NT-pro-BNP independently of renal 
function.
IntRoduCtIon
The natriuretic peptide system consists 
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Key messages
How might this impact on clinical practice?
 ► These findings suggest that during the acute phase of HF, pro-ANP 
is a more predictive biomarker with independency of renal function 
compared with NT-pro-BNP, will be one of candidates of biomarker 
in acute phases of HF.
natriuretic peptide (ANP) and the B-type and C-type 
natriuretic peptides (BNP and CNP). Whereas CNP 
is produced in the bone, central nervous system and 
vascular endothelium, BNP is predominantly produced 
from the ventricular myocardium, and ANP is mainly 
from the atrial myocardium.1 Pro-ANP, the precursor 
of mature and fully bioactive α-ANP, is stored in secre-
tory granules in atrial cardiomyocytes and it is cleaved 
into bioactive α-ANP and amino N-terminal pro-ANP 
(NT-pro-ANP) by a transmembrane proteolytic enzyme, 
corin, when it is secreted. Earlier studies also revealed 
that an antiparallel dimer of α-ANP (β-ANP) is detectable 
in the plasma of patients with heart failure (HF), along 
with α-ANP and pro-ANP.2 3 In contrast to ANP, pro-BNP 
is cleaved intracellularly into mature, fully bioactive 
BNP-32 and an (N-terminal pro-BNP) NT-pro-BNP by the 
enzyme furin. We and others previously reported that the 
molar ratio of pro-BNP to total BNP (sum of mature BNP 
plus pro-BNP) is decreased in patients with acute HF4 
or milder acute HF5 and that it is increased in patients 
with severe chronic HF (CHF)6 elevated in patients with 
severe acute HF.
In contrast to BNP, little is known about the circulating 
levels of ANP molecular forms or the regulation of their 
processing. Moreover, the clinical significance of their 
plasma levels and the molar ratio of pro-ANP to total ANP 
(sum of mature ANP, β-ANP and pro-ANP) in patients 
with HF remain unclear. In fact, there has been contro-
versy regarding the distribution of ANP molecular forms 
in the plasma of patients with HF. Using radioimmuno-
assays, Miyata et al7 found that α-ANP is the major circu-
lating form in patients with HF. On the other hand, Wei 
et al2 reported that β-ANP is the major form, accounting 
for 61% of the total plasma ANP in patients with HF. 
Although the precise reason for the discrepancy between 
the two studies is not known, it likely derives from 
differences in the methods employed (with or without 
extraction of plasma, different antibodies used for radio-
immunoassays, different columns or separation condi-
tions for chromatography). Furthermore, the clinical 
significance of the ANP molecular profile in the plasma 
has been only minimally investigated. To address these 
issues, we recently developed chemiluminescent enzyme 
immunoassays (CLEIAs) specific for total ANP, pro-ANP 
and β-ANP.8
BNP is an established biomarker predictive of future 
clinical events in patients with HF. However, plasma BNP 
levels measured on admission, when the patient is in a 
vulnerable state of acute decompensated HF (ADHF), 
are less predictive than at discharge, when the patient is 
clinically stable.9–11 Given that optimal disease manage-
ment and decision-making about treatment strategy 
require accurate clinical risk stratification on admission, 
the prognostic power of known biomarkers is not suffi-
cient in patients with ADHF. We, therefore, compared 
circulating levels of all measurable molecular forms of 
ANP and BNP in patients with ADHF. Our aims were 
to (1) investigate the associations of levels of total ANP 
and each ANP molecular form with clinical background; 
(2) assess the prognostic power of pro-ANP, β-ANP, total 
ANP, pro-BNP, NT-pro-BNP and total BNP measured in 
patients with ADHF on hospital admission and (3) inves-




This was a prospective cross-sectional study to measure 
the plasma levels of all measurable molecular forms of 
ANP and BNP in patients with ADHF admitted to our 
hospital.
study population
Eligibility requirements were as follows: (1) age from 20 
to 85 years, (2) admission to our hospital for treatment 
of ADHF, (3) enrolment within 48 hours after admission 
for ADHF and (4) provided written informed consent. 
Patients on dialysis were excluded, as were patients 
with acute coronary syndrome. In this study, patients 
who received carperitide (recombinant α-human ANP) 
before blood collection on admission were excluded. 
Ultimately, we analysed 173 patients (aged 26–85 years) 
enrolled between June 2012 and October 2015.
Biomarker testing
Details of the measurement procedures are described in 
the online supplementary methods.
Measurement of two BnP forms
Plasma total BNP and pro-BNP were measured using 
CLEIAs as previously described.5 12 NT-pro-BNP concen-
trations were measured using the Elecsys pro-BNP II 
assay (Roche Diagnostics, Basel, Switzerland). Details of 
the measurement procedures are described in the online 
supplementary methods.
Measurement of three AnP forms
Plasma total ANP, pro-ANP and β-ANP were measured 
using our recently developed plate-based CLEIAs.8 In 
brief, total ANP was measured with a sandwich CLEIA 
using antibodies recognising the C-terminal tail and the 
ring portion of ANP as the capture and detection anti-
bodies, respectively. The limit of quantification (LOQ) 
was calculated to be 0.26 pM. Intra-assay (20 replicates) 
and interassay (20 replicates) coefficients of variation 
(CV) of the standard at seven different concentra-
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respectively. Pro-ANP was quantitated using the same 
method with antibodies recognising the ring portion 
and N-terminal region of the peptide as capture and 
detection antibodies, respectively. The LOQ was 0.21 
pM. Intra-assay and interassay CVs determined under the 
same conditions used for total ANP were in the range of 
1.2%–3.7% and 3.0%–8.6%, respectively. For these two 
assays, plasma samples were diluted by twofold or more 
and directly measured using the CLEIAs. Recombinant 
FLAG-pro-ANP was used as the standard. It was custom-
made by ProCube (Kobe, Japan), purified through 
size-exclusion and reverse phase-high-performance liquid 
chromatography, and quantified by amino acid analysis.
The CLEIA for β-ANP was performed using the same 
method with an antibody recognising the ring portion 
as the capture antibody, and another specifically recog-
nising the three-dimensional structure of the molecule as 
the detection antibody. Its LOQ was 0.23 pM. Intra-assay 
and interassay CVs determined under the same condi-
tions used for total ANP were in the ranges of 0.3%–
2.8% and 4.0%–6.2%, respectively. In this assay, plasma 
samples were desalted and extracted using Sep-Pak C18 
Plus cartridges (Waters, Milford, USA), as reported previ-
ously.8 The eluate was lyophilised, reconstituted in the 
sampling buffer and applied to the β-ANP CLEIA. Quan-
tified synthetic β-ANP (Peptide Institute, Osaka, Japan) 
served as the standard.
In the total ANP CLEIA, α-ANP, β-ANP and FLAG-
pro-ANP were measured at a ratio of 1:2:1 based on the 
number of α-ANP units. In the pro-ANP CLEIA, α-ANP 
and β-ANP showed less than 0.4% cross-reactivity, while 
α-ANP and FLAG-pro-ANP showed less than 1.1% 
cross-reactivity in the β-ANP CLEIA. These three CLEIAs 
had no cross-reactivity with BNP-32 or CNP-22.8
Total ANP is sum of pro-ANP, α-ANP and beta ANP. Per 
cent pro-ANP is calculated from the following equation: 
%pro-ANP=[pro-ANP/total ANP]X100.
Cyclic guanosine monophosphate and other laboratory 
markers
Details of the measurement procedures are described in 
the online supplementary methods.
echocardiography
Echocardiography was routinely performed when the 
patients were admitted to the hospital. Details of the 
measurement procedures are described in the online 
supplementary methods.
diagnosis of AdHF
ADHF was diagnosed using the Framingham criteria.13 
The final diagnosis of cardiomyopathy was based on the 
definition from WHO/International Society and Federa-
tion of Cardiology Task Force.14
Clinical outcomes
After the admission date, we investigated all causes of 
death, implantation of a left ventricular (LV) assist device, 
and rehospitalisation for HF for 2 years through medical 
chart review or a letter. Combined clinical events were 
defined as all-cause death, implantation of an LV assist 
device or rehospitalisation for HF.
statistical analysis
Data are expressed as medians and IQR. Fisher’s exact 
test or the χ2 statistic was used to compare categorical 
variables, as appropriate. For baseline patient character-
istics, Wilcoxon’s rank-sum test was used for comparison 
of continuous variables between two groups. Univariate 
and multivariate survival analyses were performed using 
the Cox proportional hazards model. HRs with 95% CI 
and probability (p) values determined using the likeli-
hood ratio test are presented. A multiple linear regres-
sion model was used to test multiple covariates. All tests 
were two tailed, and p<0.05 was considered significant. 
All statistical analyses were performed using JMP V.9 
statistical analysis software (SAS Institute Japan).
Results
Patient characteristics
The enrolled patients with ADHF on admission were 
characterised as follows: 95% were New York Heart Asso-
ciation class III–IV on admission; the median LV ejection 
fraction (LVEF) was 34% (IQR: 23, 50%), median LV 
end-diastolic diameter (LVDd) was 56 mm (IQR: 47–64 
mm) and median hospitalisation length was 22 days 
(IQR: 14–36 days).
The histograms in figure 1 show the patient distribu-
tion plotted against the measured concentrations of each 
ANP form. In addition, online supplementary table 1 
summarises the baseline characteristics of patients whose 
plasma levels of each ANP molecular form were below 
or above the median. Patients with above median of 
these three ANP molecular forms (total ANP, β-ANP and 
pro-ANP) commonly presented with lower systolic blood 
pressure, larger LV size, lower LVEF and higher total 
BNP levels than those with below median levels. Similar 
tendencies (larger LV size and lower LVEF) were seen 
in patients with higher levels of total BNP and pro-BNP 
(p<0.05).
Prognostic power of plasma natriuretic peptide levels on 
admission in patients with AdHF
During the follow-up term (median: 469 days), composite 
clinical adverse events (all causes of death (n=27) or 
rehospitalisation for HF (n=60)) occurred in 67 patients 
(38.7 %). Table 1 shows the association between the 
plasma level of each natriuretic peptide form and clinical 
outcomes. Pro-ANP and NT-pro-BNP levels were associ-
ated with clinical outcomes in patients with ADHF. With 
the exception of pro-ANP and NT-pro-BNP, no natriu-
retic peptide form was significantly associated with the 
composite clinical adverse events. Moreover, multivariate 
analysis showed that pro-ANP levels were associated with 
composite clinical outcomes, even after adjusting for age, 
sex (table 1B), body mass index (table 1C) and estimated 
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Figure 1 Patient distribution of each ANP molecular form and %pro-ANP. (A) Total ANP (pM), (B) pro-ANP (pM), (C) β-ANP 
(pM) and (D) %pro-ANP (%). (E) Superposition of levels (pM) of total ANP (grey bars), β-ANP (blue dots) and pro-ANP (red dots). 
According to the total ANP levels, β-ANP and pro-ANP levels in each patient were plotted. n=patient number. ANP, A-type 
natriuretic peptide; NP, natriuretic peptide.
Table 1 Predictive values of natriuretic peptides (NPs) on 
admission for future clinical adverse events
Variables HR 95% CI P value
(A) Univariate analysis
Total ANP (per 10 pM) 1.01 1.00 to 1.02 0.108
β-ANP (per 10 pM) 1.14 0.93 to 1.37 0.185
Pro-ANP (per 10 pM) 1.18 1.03 to 1.34 0.018
BNP (per 10 pM) 1.02 0.99 to 1.03 0.101
Pro-BNP (per 10 pM) 1.03 1.00 to 1.05 0.058
NT-pro-BNP (per 10 pM) 1.00 1.00 to 1.01 0.002
(B) Age and sex-adjusted model
Pro-ANP (per 10 pM) 1.19 1.03 to 1.34 0.018
NT-pro-BNP (per 10 pM) 1.00 1.00 to 1.01 0.002
(C) Age, sex and BMI-adjusted model
Pro-ANP (per 10 pM) 1.07 1.02 to 1.11 0.001
NT-pro-BNP (per 10 pM) 1.00 1.00 to 1.01 0.001
(D) Age, sex and eGFR-adjusted model
Pro-ANP (per 10 pM) 1.05 1.00 to 1.10 0.046
NT-pro-BNP (per 10 pM) 1.00 1.00 to 1.01 0.062
Values expressed per 10 pM increases of each NP.
ANP, A-type natriuretic peptide;BMI, body mass index; BNP, 
B-type natriuretic peptide; eGFR, estimated glomerular filtration 
rate.
multivariate analysis adjusted by eGFR showed that 
NT-pro-BNP was not associated with clinical outcomes 
(table 1D).
Association between %pro-AnP and clinical background
Because of the strong association between plasma levels 
of pro-ANP and clinical outcome, we next assessed %pro-
ANP. Table 2 shows the clinical characteristics of patients 
whose plasma %pro-ANP levels were below or above the 
median (median %pro-ANP=9.0%). A history of HF 
hospitalisation was frequently observed in patients with 
above-median %pro-ANP levels. In addition, patients with 
above-median %pro-ANP levels were characterised with 
larger LV size, lower LVEF, lower eGFR, lower body mass 
index, high-sensitive cardiac troponin T levels and higher 
plasma BNP levels. Medications such as beta-blockers and 
aldosterone antagonists were more frequently taken by 
patients with above-median %pro-ANP. In addition, the 
frequency of persistent atrial fibrillation was tended to 
be higher in the above-median group than below-median 
%pro-ANP group, but was statistically no significant (52% 
vs 46%, respectively).
We next examined the associations between cardiac 
function/structure and the plasma concentration of each 
ANP molecular form (table 3). Plasma total ANP were not 
associated with LVDd, LVEF or left atrial diameter (LAd). 
By contrast, pro-ANP levels associated significantly with 
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Table 2 Baseline characteristics of patients with below/above median %pro-ANP
Below median %pro-ANP (<9.0%)
Above median %pro-ANP 
(≥9.0%)
Patient number 86 87
Age (years) 75 (66, 80) 76 (68, 80)
Gender (female %) 28 (33) 32 (37)
BMI (kg/m²) 24.3 (21.6, 26.6) 22.2 (20.0, 24.8)*
NYHA class
  Class III or IV, N (%) 84 (98) 80 (92)
Aetiology
  Ischaemic, N (%) 21 (24) 32 (37)
  Non-ischaemic, N (%) 14 (16) 24 (28)
  Valvular, N (%) 25 (29) 13 (15)
  Hypertensive, N (%) 18 (21) 14 (16)
  Others, N (%) 8 (9) 4 (5)
History
  HF hospitalisation, N (%) 31 (36) 46 (53)*
  Hypertension, N (%) 59 (68) 58 (67)
  DM, N (%) 36 (41) 35 (41)
  Dyslipidaemia, N (%) 46 (53) 39 (45)
Vital signs on admission
  Systolic blood pressure (mm Hg) 138 (118, 153) 130 (108, 159)
  Heart rate (bpm) 91 (73, 111) 80 (70, 97)*
Echocardiography
  LVDd (mm) 54 (47, 60) 58 (48, 67)*
  LVDs (mm) 40 (32, 52) 48 (37, 60)*
  LVEF (%) 40 (25, 53) 31 (20, 47)*
  LADs (mm) 46 (40, 51) 50 (42, 54)
Laboratory data
  Haemoglobin (g/dL) 12.5 (10.4, 13.5) 11.9 (10.6, 13.4)
  eGFR (mL/min/1.73 m²) 50.4 (37.2, 64.9) 39.7 (29.7, 54.5)*
  BUN (mg/dL) 21 (17, 28) 26 (20, 34)*
  CRP (mg/dL) 0.42 (0.17, 1.21) 0.41 (0.10, 1.94)
  hs-cTnT (ng/mL) 0.030 (0.017, 0.053) 0.040 (0.026, 0.072)*
  Plasma aldosterone concentration (ng/dL) 74.9 (37.1, 131.0) 86.6 (48.9, 186.1)
  Total plasma BNP (pmol) 93.9 (44.1, 162.7) 138.8 (81.1, 201.5)*
  Cyclic GMP (pmol/mL) 15.0 (6.4, 20.2) 12.0 (8.4, 16.0)
Medications
  ACEi or ARB, N (%) 55 (64) 52 (60)
  Beta-blockers, N (%) 55 (64) 62 (71)
  Aldosterone antagonists, N (%) 27 (31) 37 (43)
  Loop diuretics, N (%) 52 (60) 59 (68)
Values are the median (IQR) and patients number, N (%).
*P<0.05 vs below median %pro-ANP.
ACEi, angiotensin-converting enzyme inhibitor; ANP, atrial (A-type) natriuretic peptide; ARB, angiotensin II receptor blocker; BMI, body 
mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C reactive protein; DM, diabetes mellitus; GMP, guanosine 
monophosphate; HF, heart failure; hs-TnT, high sensitive cardiac troponin T; LAd, left atrial diameter; LVDd, left ventricular end-diastolic 
diameter; LVDs, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; eGFR, 
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Table 3 Relationships of natriuretic peptide molecular 
forms with cardiac structure and function
r P value
LVEF
  Total ANP 0.155 0.441
  β-ANP 0.192 0.017
  Pro-ANP 0.302 <0.0001
  Total BNP 0.423 <0.0001
  Pro-BNP 0.404 <0.0001
  NT-pro-BNP 0.244 0.001
LVDd
  Total ANP 0.058 0.473
  β-ANP 0.091 0.255
  Pro-ANP 0.262 <0.001
  Total BNP 0.269 0.0004
  Pro-ANP 0.279 0.0002
  NT-pro-BNP 0.084 0.273
LAd
  Total ANP 0.075 0.461
  β-ANP 0.111 0.272
  Pro-ANP 0.175 0.083
  Total BNP 0.150 0.138
  Pro-BNP 0.156 0.123
  NT-pro-BNP 0.108 0.289
ANP, atrial (A-type) natriuretic peptide; BNP, B-type natriuretic 
peptide; LAd, left atrial diameter; LVDs, left ventricular end-systolic 
diameter; LVEF, left ventricular ejection fraction; NT-pro-BNP, 
N-terminal fragment of pro-BNP.
Table 4 Univariate/multivariate analysis for %pro-ANP on 
admission
Variables PE P value
BMI −0.77 0.004
LVDd, mm 0.21 0.033
LVEF, % −0.15 0.024
BUN, mg/dL 0.13 0.044
eGFR, mL/min/1.73 m² −0.13 0.008
Total BNP 0.03 0.004
Age and sex-adjusted model
  BMI −0.77 0.006
  LVDd, mm 0.26 0.013
  LVEF, % −0.19 0.011
  BUN, mg/dL 0.13 0.044
  eGFR, mL/min/1.73 m² −0.13 0.012
  Total BNP 0.03 0.004
BMI, body mass index; BNP, B-type natriuretic peptide; BUN, 
blood urea nitrogen; LVDd, left ventricular end-diastolic diameter; 
LVEF, left ventricular ejection fraction; PE, parameter estimate; 
eGFR, estimated glomerular filtration rate.
Plasma levels of β-ANP were associated with LVEF. Addi-
tionally, both total BNP and pro-BNP levels associated 
with LV size and function (p<0.0001) (table 3).
Clinical determinants for %pro-AnP in patients with AdHF
Table 4 shows the univariate/multivariate analysis of 
%pro-ANP for the listed clinical variables (upper panel: 
age and sex-unadjusted model, lower panel: age and 
sex-adjusted model). The association between %pro-ANP 
of all variables persisted even after the adjustments for 
age and sex.
dIsCussIon
On admission, in a vulnerable state of ADHF, there is still 
an unmet need for a biomarker for prediction of future 
clinical outcomes. In the present study, we used highly 
sensitive and specific immunoassays to measure six forms 
of ANP and BNP in patients with ADHF on their hospital 
admission and to determine the peptides’ associations 
with clinical data. Among the six peptide forms, pro-ANP 
and NT-pro-BNP levels on admission were predictive 
of future adverse clinical events in patients with ADHF 
(table 1), even compared with total BNP and pro-BNP 
levels. Comprehensive analyses clearly showed that a 
higher pro-ANP-to-total ANP ratio (%pro-ANP) is asso-
ciated with both larger LV size and lower LVEF, which 
suggests that higher pro-ANP levels are associated with 
more advanced LV remodelling (tables 3 and 4).
differences in the synthesis, secretion and metabolism of AnP 
and BnP
Although ANP and BNP activate the same transmem-
brane receptor (natriuretic peptide receptor-A) and 
exert similar physiological effects, the regulation of their 
gene expression, post-translational processing, secretion 
and metabolism differs. Pro-ANP is stored in secretory 
granules in atrial myocytes as the prohormone pro-ANP. 
By contrast, BNP is predominantly secreted from the 
ventricular myocardium via a constitutive pathway and is 
present as a mixture of pro-BNP and mature BNP.15 16
In patients with HF, the cardiac secretion profile for 
ANP reportedly differs from that in healthy subjects. By 
measuring and comparing samples collected from the 
aortic root, coronary sinus and anterior interventricular 
vein, Yasue et al17 showed that plasma ANP levels increase in 
proportion to the severity of LV dysfunction and haemody-
namic disorder. The precise mechanisms responsible for 
ventricular dominancy for ANP synthesis in these patients 
remain uncertain even at present. Earlier studies indicate 
that ANP is abundantly expressed in human ventricles 
during fetal stages, but its expression in the developing 
heart declines as gestation progresses.18 19 Interestingly, 
these reports indicated that ANP production and secre-
tion shift from the atria to the ventricles in patients with 
severe HF.19 Several other groups also reported marked 
elevation in ventricular ANP expression in patients with 
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predominance of the fetal gene programme is observed 
in failing human hearts.15 16 The evidence that ventricular 
expression and secretion of ANP is increased in patients 
with severe HF appears consistent with a return to the 
fetal gene programme, although a distribution of each 
molecular form of ANP secreted into the circulation in 
severe HF remains unknown. Recently, Nishikimi et al23 
reported that pro-ANP is the major ANP form secreted 
from cultured rat neonatal ventricular myocytes (>50% 
of total ANPs), while α-ANP was dominant in cultured rat 
fetal atrial myocytes. Collectively, these results suggest that 
increased ventricular synthesis and secretion of pro-ANP 
in patients with severe HF may result in the strong associ-
ation of plasma pro-ANP levels with LV dysfunction and 
larger LV size. In the present study, we found that %pro-
ANP (pro-ANP-to-total ANP ratio) is also associated with 
LV size and function in patients with ADHF (tables 3 and 
4). To the best of our knowledge, this is the first study 
to demonstrate the association of %pro-ANP with cardiac 
structure and function. Because these findings suggest 
dysregulation of pro-ANP secretion or metabolism in 
patients with ADHF, it will be necessary to investigate the 
molecular mechanism that makes pro-ANP dominant in 
the plasma of patients with advanced LV remodelling. On 
the other hand, atrial cardiomyocytes store high levels of 
pro-ANP in granules, and previous reports showed that 
plasma ANP responds more quickly than BNP to acute 
physiological changes, such as those induced by exer-
cise24 or experimental pacing stimulation.25 However, 
given the strong association between pro-ANP levels 
and ventricular variables detected, rather than left atrial 
size, in the present study, these findings could indicate 
that ANP synthesis and secretion from the ventricle 
and dysregulation of pro-ANP processing, rather than 
the early responsiveness of ANP secreted from atrium, 
contribute to the elevation in plasma pro-ANP levels and 
the higher %pro-ANP. These findings also raise the possi-
bility that pro-ANP could be a biomarker of a ventricular 
‘trait’ rather than a haemodynamic marker such as BNP 
levels, but further investigation will be necessary to test 
that idea.
Comparing prognostic power of AnP and BnP
Tsutamoto et al26 reported that plasma BNP is more 
useful than ANP for assessing mortality among patients 
with CHF. This is generally explained by the longer half-
life of BNP (half-life: 12 to22 min) as compared with ANP 
(half-life: 2–5 min).27 BNP or NT-pro-BNP levels during 
chronic phases of HF (patients at discharge from hospital 
or ambulatory patients) are now well established as prog-
nostic biomarkers, but BNP on admission is less predic-
tive in patients with ADHF. Because earlier studies mainly 
focused on patients during the chronic phase of HF, 
there has been little data available to compare the prog-
nostic power of ANP and BNP, especially for their various 
molecular forms, including precursors. The detection of 
a strong association between plasma pro-ANP levels and 
long-term clinical outcomes in the present study may 
shed new light on these issues.
This study showed that pro-ANP has a prognostic 
power comparable with NT-pro-BNP, and interestingly, 
multivariate analysis showed that statistical significance 
of prognostic power of NT-pro-BNP was diminished in 
the multivariate analysis adjusted by eGFR, but that of 
pro-ANP persisted in the same analysis. These findings 
suggest that NT-pro-BNP provides the information, but 
dependent of renal function. In contrast, pro-ANP is 
statistically independent of renal function in this study, 
and these findings suggest that pro-ANP provides the 
information of ventricular quality independent of renal 
function compared with NT-pro-BNP. Additionally, the 
analysis in this study also demonstrated that NT-pro-BNP, 
but not BNP, was associated with clinical outcomes in 
patients with ADHF. Several previous studies compared 
the prognostic power of NT-pro-BNP and BNP in patients 
with HF on hospital admission28 and before discharge.29 
One study showed the similar tendency to this study in 
that NT-pro-BNP had the stronger prognostic power 
for clinical outcomes in patients with ADHF on hospital 
admission.28
After treatment of ADHF, plasma levels of ANP and BNP 
levels often greatly decline with haemodynamic improve-
ment. Therefore, natriuretic peptide levels detected after 
normalisation of haemodynamics or removal of excess 
body fluid volume may indicate the severity of the HF 
itself; in other words, only after removal of excess body 
fluid BNP levels are predictive of future clinical outcomes. 
BNP levels before discharge from the hospital, thus, 
reflect the haemodynamic state after removal of excess 
body fluid, which would explain why levels measured 
during the acute phase of HF are less predictive. It may 
be that in the presence of excess fluid volume, BNP levels 
do not reflect the ‘true ventricular trait’. By contrast, 
our results suggest that pro-ANP levels at admission are 
robustly associated with ventricular function and size, 
suggesting a reflection of the qualitative abnormality of 
the ventricle, which is why pro-ANP at admission may be 
indicative of prognosis.
limitations
The present study has several limitations. First, it was a 
single-centre investigation performed with a limited 
number of patients. Second, we excluded patients who 
had received carperitide before blood collection because 
we could not exclude the possibility that carperitide 
affects metabolism of pro-ANP, which could cause selec-
tion bias. Third, a system that measures α-ANP specifi-
cally has not been established, plasma α-ANP levels 
remain uncertain in this study. Further investigation will 
be necessary to measure all natriuretic peptides including 
α-ANP. Percent pro-ANP indicates a ratio of uncleaved 
pro-ANP to total ANP. In the clinical settings, it has been 
hard to measure the pro-ANP processing in patients with 
acute HF because of a lack of a clinically available assay 
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elucidate the pro-ANP processing directly at present. 
Based on this background, we consider %pro-ANP as an 
estimated index of unprocessed pro-ANP rate. Since it 
is controversial to determine that %pro-ANP (median: 
9%) is corresponding to pro-ANP processing in the clin-
ical settings, further investigation will be necessary to 
confirm this issue. Meanwhile, because of the strong rela-
tionship of %pro-ANP with ventricular systolic function, 
rather, this value can be a possible candidate to indicate 
the ventricular quality. Fourth, the statistical difference 
in the prognostic power of the natriuretic peptides was 
moderate. Importantly, larger cohort studies with patients 
with ADHF are necessary to determine the superiority of 
prognostic power of pro-ANP to that of NT-pro-BNP in 
patients with acute HF on hospital admission. Lastly, we 
could not collect the sufficient number of patients with 
HF with preserved EF for the statistical analysis (HFpEF, 
n=29). Because quarter to half of patients with HF are 
categorised as HFpEF,30 31 careful interpretation will be 
necessary to expand these findings to entire patients with 
HF.
ConClusIon
In summary, we were able to measure circulating levels of 
six molecular forms of ANP and BNP, including pro-ANP, 
β-ANP and total ANP, during the acute phase of HF. Our 
findings demonstrate that pro-ANP levels on admission 
have a close association with the degree of LV remodel-
ling and are therefore strongly predictive of outcome in 
patients with ADHF, with independency of renal func-
tion. Consequently, pro-ANP may be a better prognostic 
marker than BNP and NT-pro-BNP during the acute 
phase of HF.
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